Cancer Tissue Diagnostics Market Growing Investments for Tissue Diagnostics
The cancer tissue diagnostics market is US$ 2,025.41 Mn in 2018 and is predicted to grow at a CAGR of 6.2% during the forecast period 2019 – 2027, to reach US$ 3,419.61 Mn by 2027.
Europe is the second largest geographic market and is expected to be the second most significant revenue contributor in forecast period. The region has witnessed several technological advancements in the field of healthcare by the incorporation of advanced cancer tissue diagnostics in order to increase the efficiency of treatments in the region. The growth is driven by factors such as prevalence of cancer in the countries, increased mortality rates as well as growth strategies adopted by the market players in the European countries.
Cancer is among the leading cause of deaths across the globe and is profoundly affecting the quality of life. Thus, cancer will be a burden on society if not diagnosed and treated on time. According to the World Health Organization in 2018, approximately 9.6 million deaths across the globe were due to cancer. Furthermore, the National Cancer Institute predicted that in 2018, approximately 1,735,350 new cancer cases would be diagnosed in the US.
Request sample of this research report at: https://www.theinsightpartners.com/sample/TIPRE00005672/
Key findings from the report
The global cancer tissue diagnostics market by test type was led by immunohistochemical tests segment. In 2018, the immunohistochemical tests segment held a largest market share of the cancer tissue diagnostics market, by test type. In addition, the immunohistochemical tests segment is also expected to grow at the fastest rate during the coming years owing to cost effectiveness of the technique. Moreover, the technique is easily accessible, and growth in number of products based on technology. Additionally, the rising prevalence of cancer is a major factor for the growth of the diagnostic tests. The segment is also anticipated to witness growth at a significant rate during the forecast period, 2019 to 2027.
There have been limited developments made in the cancer tissue diagnostics market during recent years. However, growth strategies such as approvals, collaborations, and partnerships have been witnessed in the market of cancer tissue diagnostics. For instance, in June 2019, Agilent Technologies Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-L1 IHC 22C3 pharmDx assay. The assay is approved to aim in identifying patients with head and neck squamous cell carcinoma (HNSCC) for treatment with KEYTRUDA (pembrolizumab), anti-PD-1 therapy manufactured by Merck. Also, during November 2018, Leica Biosystems, launched the latest PD-L1 antibody for use on their fully automated BOND IHC and ISH staining platform.
The major players operating in the cancer tissue diagnostics market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Bio Rad Laboratories Inc., Abbott, Enzo Life Sciences, Inc., Agilent Technologies, Inc., Cancer Genetics Inc., Merck KGaA (Sigma-Aldrich Co. LLC), Danaher Corporation, and Abcam plc. The market has witnessed various organic as well as inorganic developments during recent years in the Cancer Tissue Diagnostics market. For instance, during June 2019, Agilent Technologies Inc. received the FDA approval for PD-L1 IHC 22C3 pharmDx assay. The assay is approved to identifying patients with head and neck squamous cell carcinoma (HNSCC) for treatment with KEYTRUDA (pembrolizumab), anti-PD-1 therapy manufactured by Merck.
Cancer Tissue Diagnostics Market to 2027 - Global Analysis and Forecasts By Test Type (Immunohistochemical Tests and In Situ Hybridization Tests) and Geography
For the purpose of this report, Reports and Data has segmented the global cancer tissue diagnostics market on the basis of type, product, platform, end user, and region:
By Test Type
- Immunohistochemical Tests
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- In Situ Hybridization Tests
- Breast Cancer
- Lung Cancer
- Bladder Cancer
- North America
- Asia Pacific (APAC)
- South Korea
- Middle East & Africa (MEA)
- Saudi Arabia
- South Africa
- South and Central America
Browse similar research reports:
Ovarian Cancer Drugs Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography
Cancer Immunotherapy Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Therapy (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines); Application (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, Head and neck cancer, Ovarian cancer, Others); End User (Hospitals, Ambulatory Surgery Centers, Cancer Research Centers, Specialty Clinics) and Geography
Place an Order Now: https://www.theinsightpartners.com/buy/TIPRE00005672/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.
Contact Person: Sameer Joshi
Email Id- firstname.lastname@example.org